G
Gemtuzumab Ozogamicin
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Subsidy Information and Financing Scheme
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Medical Assistance Fund
Active ingredient: Gemtuzumab Ozogamicin
General information
Subsidy Information and Financing Scheme
[MAF] Gemtuzumab ozogamicin (Mylotarg) Concentrate For Infusion 5 mg
In combination with daunorubicin and cytarabine for patients with previously untreated de novo CD33-positive acute myeloid leukaemia (AML), if they:
• do not have acute promyelocytic leukaemia,
• only start induction therapy while waiting for cytogenetic test results or after confirming favourable, intermediate or unknown (due to inconclusive test results) cytogenetic risk, and
• start consolidation therapy after confirming favourable, intermediate, or unknown cytogenetic risk.
[MSHL] Gemtuzumab ozogamicin Powder For Concentrate For Solution For Infusion Vial 5 mg
In combination with daunorubicin and cytarabine for patients with previously untreated de novo CD33-positive acute myeloid leukaemia (AML), if they:
• do not have acute promyelocytic leukaemia,
• only start induction therapy while waiting for cytogenetic test results or after confirming favourable, intermediate or unknown (due to inconclusive test results) cytogenetic risk, and
• start consolidation therapy after confirming favourable, intermediate, or unknown cytogenetic risk.
Drug Guidance for Subsidy
31/08/2022 Gemtuzumab ozogamicin for untreated de novo CD33-positive acute myeloid leukaemia
The Ministry of Health’s Drug Advisory Committee has recommended:
Gemtuzumab ozogamicin 5 mg powder for concentrate for solution for infusion in combination with daunorubicin and cytarabine for patients with previously untreated de novo CD33-positive acute myeloid leukaemia (AML), if they:
do not have acute promyelocytic leukaemia,
only start induction therapy while waiting for cytogenetic test results or after confirming favourable, intermediate or unknown (due to inconclusive test results) cytogenetic risk, and
start consolidation therapy after confirming favourable, intermediate, or unknown cytogenetic risk.
Funding status
[R] Gemtuzumab ozogamicin 5 mg powder for concentrate for solution for infusion is recommended for inclusion on the Cancer Drug List (Medication Assistance Fund and MediShield Life monthly claim limit of SG$3200) for the abovementioned indication from 1 September 2022.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Mylotarg Concentrate For Infusion 5 mg |
|